Pashtoon Kasi, Medical Director of GI Medical Oncology at City of Hope Orange County, shared on X:
“Full paper of my investigator initiated NEST trial now available in print Clinical Cancer Research.
Trending number 1 based on all the discussion and enthusiasm around neoadjuvant immunotherapy for patients with MSS colorectal cancer. New paradigm.”
Title: Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
Authors: Manish A. Shah, Erika Hissong, Mehraneh D. Jafari, Pashtoon Murtaza Kasi, Maider Astorkia, Sahrish Khan, Casey Owens, Zhengming Chen, Heather Yeo, Fabio Socciarelli, Sandipto Sarkar, Alana Nguyen, Despina Siolas, Allyson Ocean, Kelly Garrett, Lea Lowenfeld, Alessio Pigazzi, Preethi Guniganti, Sanjay Patel, Doron Betel, Manuel Hidalgo
Read The Full Article
You may also be interested in: Tumor Mutational Burden Predicts Response to Neoadjuvant Immunotherapy
